Anzeige
Mehr »
Login
Mittwoch, 03.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Ad-hoc: Kursrelevant!? 300%-Steigerung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 659157 ISIN: US2561352038 Ticker-Symbol: RDDA 
Frankfurt
02.03.21
16:30 Uhr
50,000 Euro
+0,40
+0,81 %
Branche
Pharma
Aktienmarkt
S&P BSE SENSEX
1-Jahres-Chart
DR REDDYS LABORATORIES LTD ADR Chart 1 Jahr
5-Tage-Chart
DR REDDYS LABORATORIES LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
49,60050,5002.03.

Aktuelle News zur DR REDDYS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrDr. Reddy's Recalls Prescription Drug Blister Packages273NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories, Inc. is recalling about 21,400 blister packages of certain prescription medications citing the risk of poisoning to children, the U.S. Consumer...
► Artikel lesen
DoDr. Reddy's requested by India to give more data for Sputnik V approval-
DR REDDYS Aktie jetzt für 0€ handeln
DoStocks in the news: Nureca, Dr Reddy's Labs, Affle India, Max Financial and HGS1
DoDr Reddy's fails to get approval for Sputnik V1
23.02.Dr. Reddy's gets FDA nod for orally disintegrating lansoprazole1
22.02.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer-
22.02.Stock market update: Nifty Pharma index falls nearly 2%; Dr Reddy's Lab down 4%1
22.02.Dr. Reddy's launches generic Prevacid SoluTab tablets in U.S.-
22.02.Dr Reddy's launches stomach, esophagus problems treatment drug in the US1
22.02.Dr. Reddy's Labs Launches Lansoprazole DR Orally Disintegrating Tablets In U.S.163NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) said Monday that it has launched Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid...
► Artikel lesen
19.02.Dr Reddy's seeks urgent use permit for Sputnik V1
19.02.Dr. Reddy's Starts EUA Process For Russia's Sputnik V COVID-19 Vaccine In India-
19.02.Dr. Reddy's Begins EUA Process In India For Sputnik V Vaccine214NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization of the vaccine candidate, Sputnik...
► Artikel lesen
19.02.Dr. Reddy's seeks emergency use nod for Sputnik V in India1
19.02.Dr. Reddy's Laboratories Ltd.: Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V225Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has initiated the process...
► Artikel lesen
19.02.Dr Reddy's seeks emergency use authorization for Russia's Sputnik V vaccine1
18.02.Dr. Reddy's launches generic Prolixin tablets in U.S.-
17.02.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer-
17.02.Dr. Reddy's Launches Generic Version Of Xeloda Tablets203NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version...
► Artikel lesen
17.02.Dr. Reddy's launches generic capecitabine tablets in U.S.1
Seite:  Weiter >>
181 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1